drugset / Trial / NCT05654506
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Timeline
- Start
- 2023-08-17
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |